| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b94d2715cda37c1f23e48f9f4f23422 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-30 |
| filingDate |
2010-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d15a5318da2a0a4efc1c158629dfe41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7e3949013e05bad982e8fb5939c3ca2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_244d65bdfa483b26686dfef495edc396
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34319441b86fbb4102d986f26c40b3f1 |
| publicationDate |
2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3002946-C |
| titleOfInvention |
Plasmodium falciparum sporozoite and liver stage antigens |
| abstract |
The invention provides novel malaria polypeptides expressed at the pre- erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation. |
| priorityDate |
2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |